[go: up one dir, main page]

MX2017016114A - Metodos para tratar o prevenir una proteopatia. - Google Patents

Metodos para tratar o prevenir una proteopatia.

Info

Publication number
MX2017016114A
MX2017016114A MX2017016114A MX2017016114A MX2017016114A MX 2017016114 A MX2017016114 A MX 2017016114A MX 2017016114 A MX2017016114 A MX 2017016114A MX 2017016114 A MX2017016114 A MX 2017016114A MX 2017016114 A MX2017016114 A MX 2017016114A
Authority
MX
Mexico
Prior art keywords
proteopathy
methods
treating
preventing
prevention
Prior art date
Application number
MX2017016114A
Other languages
English (en)
Inventor
Saperstein David
Original Assignee
Usher Iii Initiative Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Usher Iii Initiative Inc filed Critical Usher Iii Initiative Inc
Publication of MX2017016114A publication Critical patent/MX2017016114A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se describen métodos para el tratamiento o prevención de una proteopatía.
MX2017016114A 2015-06-11 2016-06-10 Metodos para tratar o prevenir una proteopatia. MX2017016114A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562174338P 2015-06-11 2015-06-11
US201562174332P 2015-06-11 2015-06-11
PCT/US2016/036945 WO2016201266A1 (en) 2015-06-11 2016-06-10 Methods of treating or preventing a proteopathy

Publications (1)

Publication Number Publication Date
MX2017016114A true MX2017016114A (es) 2018-04-11

Family

ID=57503990

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016114A MX2017016114A (es) 2015-06-11 2016-06-10 Metodos para tratar o prevenir una proteopatia.

Country Status (10)

Country Link
US (2) US20180099974A1 (es)
EP (1) EP3307742B1 (es)
JP (4) JP6924155B2 (es)
AU (1) AU2016274956A1 (es)
CA (1) CA2986785A1 (es)
ES (1) ES2924433T3 (es)
IL (1) IL256109A (es)
MX (1) MX2017016114A (es)
WO (1) WO2016201266A1 (es)
ZA (1) ZA201708082B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2834049C (en) 2011-04-25 2018-05-22 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
US9227976B2 (en) 2012-10-25 2016-01-05 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
EP3628044B1 (en) * 2017-05-15 2023-11-22 The Regents of The University of Michigan Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors
CN111171019A (zh) * 2018-11-13 2020-05-19 上海轶诺药业有限公司 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
WO2020106825A1 (en) 2018-11-20 2020-05-28 Georgetown University Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders
EP3937942A4 (en) * 2019-03-15 2022-11-16 Skyhawk Therapeutics, Inc. COMPOSITIONS AND METHODS FOR CORRECTING ABERRANT SPLICING
EP4178580B1 (en) * 2020-07-09 2025-11-05 Usher III Initiative, Inc. Bf 844 for use in the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011162655A1 (en) * 2010-06-24 2011-12-29 Alphabeta Ab Compound and method for treatment of alzheimer's disease and familial dementia
CA2834049C (en) 2011-04-25 2018-05-22 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
US9845327B2 (en) 2011-06-22 2017-12-19 The General Hospital Corporation Treatment of proteinopathies
US9227976B2 (en) 2012-10-25 2016-01-05 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
US8765762B2 (en) * 2012-10-25 2014-07-01 Usher III, Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome

Also Published As

Publication number Publication date
HK1252692A1 (zh) 2019-05-31
JP2023071887A (ja) 2023-05-23
AU2016274956A1 (en) 2017-12-14
JP2021178849A (ja) 2021-11-18
EP3307742A1 (en) 2018-04-18
CA2986785A1 (en) 2016-12-15
ZA201708082B (en) 2021-03-31
US20240279229A1 (en) 2024-08-22
EP3307742B1 (en) 2022-05-18
JP6924155B2 (ja) 2021-08-25
ES2924433T3 (es) 2022-10-06
JP2025106385A (ja) 2025-07-15
JP7755610B2 (ja) 2025-10-16
IL256109A (en) 2018-02-28
JP2018521026A (ja) 2018-08-02
WO2016201266A1 (en) 2016-12-15
US20180099974A1 (en) 2018-04-12
EP3307742A4 (en) 2019-03-06

Similar Documents

Publication Publication Date Title
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
IL269371A (en) Treatment methods
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
MA40404A (fr) Polythérapie pour traiter un paramyxovirus
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
PH12017501999A1 (en) K-ras modulators
PH12018502020A1 (en) Methods for treating and preventing c. difficile infection
GB2541571A (en) Pharmaceutical compositions
EA201891340A1 (ru) Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек
ZA201700416B (en) Methods for treating or preventing ophthalmological conditions
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
EA201991818A1 (ru) Лечение рака
MA40457A (fr) Combinaison de médicaments pour traiter le myélome multiple
GB201813876D0 (en) Treatment
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
PH12017501864A1 (en) Compositions and methods for treating autism
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
IL252197A0 (en) A method for treating, preventing or reducing the risk of skin infection
ZA201806806B (en) Method for the treatment or prevention of osteoarthritis.
GB201819924D0 (en) Treatment method
SG11202001806TA (en) Treatment method
GB201800546D0 (en) Treatment
SG11202102827YA (en) Treatment methods
SG11202102878TA (en) Treatment methods
ZA202001536B (en) Method for the treatment of wastewaters